Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 4, Number 5-6, December 2014, pages 143-147

Tocilizumab Increases Serum Adiponectin and Reduces Serum Fatty Acid Binding Protein 4 in Patients With Rheumatoid Arthritis

Figures

Figure 1.
Figure 1. Treatment with tocilizumab increased serum adiponectin (A) and decreased fatty acid-binding protein 4 levels (B) in patients with RA. Bars represent mean ± SEM.
Figure 2.
Figure 2. (A) Effects of interleukin-6 (IL-6) and tocilizumab on adiponectin production in human adipocytes. Cells were differentiated for 12 days, and then treated without (control) or with 10 µg/mL IL-6 antibody, and/or 100 µg/mL, or 10 mg/mL tocilizumab. Data are presented as means ± SEM of at least four independent experiments. *P < 0.05; **P < 0.01 vs. control. Pio: pioglitazone. (B) Effects of interleukin-6 (IL-6) and tocilizumab on fatty acid-binding protein 4 levels in human adipocytes. Cells were differentiated for 12 days and treated without (control) or with 10 µg/mL IL-6 antibody, and/or 100 µg/mL, 10 mg/ml or tocilizumab. Data are expressed as means ± SEM of at least four independent experiments.*P < 0.05; **P < 0.01 vs. control. Pio: pioglitazone. (C) A representative western blot of fatty acid-binding protein 4 expression in human adipocytes treated without (control) or with 10 µg/mL interleukin-6 antibody, and/or 100 µg/mL, or 10 mg/mL tocilizumab. Pio: pioglitazone.